Publication: Impact of enhanced compliance initiatives on the efficacy of rosuvastatin in reducing low density lipoprotein cholesterol levels in patients with primary hypercholesterolaemia
Impact of enhanced compliance initiatives on the efficacy of rosuvastatin in reducing low density lipoprotein cholesterol levels in patients with primary hypercholesterolaemia
Date
Date
Date
Citations
Riesen, W. F., Noll, G., & Darioli, R. (2008). Impact of enhanced compliance initiatives on the efficacy of rosuvastatin in reducing low density lipoprotein cholesterol levels in patients with primary hypercholesterolaemia. Swiss Medical Weekly, 138, 420–426. http://www.smw.ch/docs/pdf200x/2008/29/smw-12120.pdf
Abstract
Abstract
Abstract
BACKGROUND: The effectiveness of lipid-lowering medication critically depends on the patients' compliance and the efficacy of the prescribed drug. OBJECTIVES: The primary objective of this multicentre study was to compare the efficacy of rosuvastatin with or without access to compliance initiatives, in bringing patients to the Joint European Task Force's (1998) recommended low-density lipoprotein cholesterol (LDL-C) level goal (LDL-C, <3.0 mmol/L) at week 24. Secondary objectives were comparison of the number and percentage of patient
Metrics
Downloads
Views
Additional indexing
Creators (Authors)
- Riesen, W F
- Noll, G
Volume
Volume
Volume
Number
Number
Number
Page range/Item number
Page range/Item number
Page range/Item number
Page end
Page end
Page end
Item Type
Item Type
Item Type
In collections
Dewey Decimal Classifikation
Dewey Decimal Classifikation
Dewey Decimal Classifikation
Language
Language
Language
Publication date
Publication date
Publication date
Date available
Date available
Date available
ISSN or e-ISSN
ISSN or e-ISSN
ISSN or e-ISSN
Additional Information
Additional Information
Additional Information
OA Status
OA Status
OA Status
Free Access at
Free Access at
Free Access at
Metrics
Downloads
Views
Citations
Riesen, W. F., Noll, G., & Darioli, R. (2008). Impact of enhanced compliance initiatives on the efficacy of rosuvastatin in reducing low density lipoprotein cholesterol levels in patients with primary hypercholesterolaemia. Swiss Medical Weekly, 138, 420–426. http://www.smw.ch/docs/pdf200x/2008/29/smw-12120.pdf
